IDiyas

For the Inventor, By the Inventor

Slingerlands, NY, United States of America

Bruce Francis Molino

USPTO Granted Patents = 41


 

Average Co-Inventor Count = 3.4

ph-index = 15

Forward Citations = 713(Granted Patents)


Company Filing History:

goldMedal18 out of 97 
 
Albany Molecular Research, Inc.
 patents
silverMedal11 out of 83 
 
Parion Sciences, Inc.
 patents
bronzeMedal8 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
4. 5 out of 23 
 
Amr Technology, Inc.
 patents
5. 5 out of 24 
 
Zenith Epigenetics Corp.
 patents
6. 1 out of 207 
 
Aventis Pharmaceuticals Inc.
 patents
7. 1 out of 23 
 
Aventis Pharmaceuticals Products Inc.
 patents
where one patent can have more than one assignee

Years Active: 2001-2020

Loading Chart...
Loading Chart...
Loading Chart...
41 patents (USPTO):
1. 10710992 - Substituted pyridinones as bromodomain inhibitors (2020-07-14),
2. 10179125 - Substituted pyridines as bromodomain inhibitors (2019-01-15),
3. 9861637 - Heterocyclic compounds as bromodomain inhibitors (2018-01-09),
4. 9604960 - Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof (2017-03-28),
5. 9598367 - Heterocyclic compounds as bromodomain inhibitors (2017-03-21),
6. 9499531 - Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin (2016-11-22),
7. 9403776 - Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin (2016-08-02),
8. 9271978 - Heterocyclic compounds as bromodomain inhibitors (2016-03-01),
9. 9096546 - Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin (2015-08-04),
10. 9085531 - Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin (2015-07-21),
11. 9045468 - 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin (2015-06-02),
12. 9034899 - Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof (2015-05-19),
13. 8987252 - Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin (2015-03-24),
14. 8802696 - 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof (2014-08-12),
15. 8791101 - Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin (2014-07-29),

Title: The Innovative Journey of Bruce Francis Molino

Introduction: Bruce Francis Molino, a talented inventor hailing from Slingerlands, NY (US), has made significant contributions to the field of innovations with his creative mind and dedication to problem-solving.

Latest Patents: Bruce Francis Molino holds several patents in various industries, showcasing his versatility and ingenuity in inventing new solutions to complex challenges.

Career Highlights: Throughout his career, Bruce Francis Molino has demonstrated a keen ability to identify gaps in the market and develop groundbreaking inventions to fill those voids. His passion for innovation has led to the creation of revolutionary products that have improved the lives of many.

Collaborations: Bruce Francis Molino has collaborated with leading companies and research institutions to bring his inventions to life. His ability to work effectively in a team setting has allowed him to leverage the expertise of others and achieve remarkable results.

Conclusion: Bruce Francis Molino's relentless pursuit of innovation and his commitment to pushing the boundaries of what is possible make him a true pioneer in the world of inventions. His impact on various industries is undeniable, and his legacy as an inventor will continue to inspire future generations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…